BEAMNEUTRAL

EV/EBITDA

-7.2x

Higher than 9% of Healthcare sector peers

Updated 22h ago

Sector Performance

9th percentile

BEAM

-7.2x

Sector Median

12.8x

Sector Avg

15.6x

📊

Deep Analysis

The current EV/EBITDA of -7.2x means Beam Therapeutics has a negative enterprise value relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA), indicating the company is generating losses rather than profits.

This places the company at the 9th percentile among sector peers, well below the healthcare sector median of 12.8x. The year-over-year change is not available, but the quarter-over-quarter change is +92.2%, moving from -91.6x to -7.2x as the most recent pair of values. The combination of a deeply negative EV/EBITDA with a sharp improvement over the prior quarter reflects persistent losses but a rapid narrowing of those losses, which reduces near-term risk while still signaling unprofitability. This mixed profile—negative but sharply improving—supports the overall NEUTRAL verdict, as the metric neither confirms a strong opportunity nor strongly contradicts a cautious outlook.

Frequently Asked Questions

What does the EV/EBITDA tell investors about BEAM?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does BEAM's EV/EBITDA compare to its sector?

BEAM's EV/EBITDA of -7.2x compares to a Healthcare sector median of 12.8x, placing it in the 9th percentile.

Who are BEAM's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: BDX (12.2x), GSK (10.2x), CPRX (10.1x), ZBH (9.7x), BAX (9.4x).

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.